AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
lenacapavir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antivirals | 5704 | 2189684-44-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between capsid protein (CA) subunits. Lenacapavir inhibits HIV-1 replication by interfering with multiple, essential steps of the viral lifecycle, including capsid-mediated nuclear uptake of HIV-1 proviral DNA (by blocking nuclear import proteins binding to capsid), virus assembly and release (by interfering with Gag/Gag-Pol functioning, reducing production of CA subunits), and capsid core formation (by disrupting the rate of capsid subunit association, leading to malformed capsids).
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.19 | g | O |
| 5.10 | mg | P |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | PDK1,PDK2,PDK4 | 3 | |||
| kinase-selectivity-class | PDK1 | 1 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 17, 2022 | EMA | GILEAD SCIENCES IRELAND UNLIMITED COMPANY | |
| Dec. 22, 2022 | PMDA | GILEAD SCIENCES |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Injection site discharge | 1053.47 | 99.41 | 123 | 640 | 402 | 42620170 |
| Injection site nodule | 428.14 | 99.41 | 66 | 697 | 2095 | 42618477 |
| Product use in unapproved therapeutic environment | 284.38 | 99.41 | 37 | 726 | 321 | 42620251 |
| Injection site pain | 242.26 | 99.41 | 73 | 690 | 57725 | 42562847 |
| Injection site erythema | 103.50 | 99.41 | 30 | 733 | 20165 | 42600407 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Injection site discharge | 520.53 | 78.30 | 64 | 492 | 1396 | 110587347 |
| Product use in unapproved therapeutic environment | 226.25 | 78.30 | 26 | 530 | 298 | 110588445 |
| Injection site nodule | 207.38 | 78.30 | 33 | 523 | 4613 | 110584130 |
| Injection site pain | 142.06 | 78.30 | 47 | 509 | 177875 | 110410868 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J05AX31 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Other antivirals |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000998 | Antiviral Agents |
| MeSH PA | D019380 | Anti-HIV Agents |
| MeSH PA | D044966 | Anti-Retroviral Agents |
| FDA MoA | N0000185503 | P-Glycoprotein Inhibitors |
| FDA MoA | N0000190113 | Breast Cancer Resistance Protein Inhibitors |
| FDA MoA | N0000190114 | Cytochrome P450 3A Inhibitors |
| FDA MoA | N0000194086 | HIV Capsid Inhibitors |
| FDA EPC | N0000194088 | Human Immunodeficiency Virus 1 Capsid Inhibitor |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:64946 | anti-HIV agent |
| CHEBI has role | CHEBI:64947 | anti-HIV-1 agent |
Related Drugs by ATC class:
J05AX Other antivirals 15 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Multidrug resistant HIV-1 infection | indication | 40780007 | |
| Drug induction of cytochrome p450 CYP3A enzyme | contraindication | 423236002 | |
| Co-administration with P-gp inducers | contraindication | ||
| Co-administration with UGT1A1 inducers | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SUNLENCA | GILEAD SCIENCES INC | N215973 | Dec. 22, 2022 | RX | SOLUTION | SUBCUTANEOUS | 9951043 | Feb. 28, 2034 | IN COMBINATION WITH OTHER ANTIRETROVIRAL(S), FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY-TREATMENT EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION |
| EQ 300MG BASE | SUNLENCA | GILEAD SCIENCES INC | N215974 | Dec. 22, 2022 | RX | TABLET | ORAL | 9951043 | Feb. 28, 2034 | IN COMBINATION WITH OTHER ANTIRETROVIRAL(S), FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY-TREATMENT EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION |
| EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | YEZTUGO | GILEAD SCIENCES INC | N220018 | June 18, 2025 | RX | SOLUTION | SUBCUTANEOUS | 9951043 | Feb. 28, 2034 | FOR PRE-EXPOSURE PROPHYLAXIS TO REDUCE THE RISK OF SEXUALLY ACQUIRED HIV-1 IN ADULTS AND ADOLESCENTS WEIGHING AT LEAST 35 KG WHO ARE AT RISK FOR HIV-1 ACQUISITION |
| EQ 300MG BASE | YEZTUGO | GILEAD SCIENCES INC | N220020 | June 18, 2025 | RX | TABLET | ORAL | 9951043 | Feb. 28, 2034 | FOR PRE-EXPOSURE PROPHYLAXIS TO REDUCE THE RISK OF SEXUALLY ACQUIRED HIV-1 IN ADULTS AND ADOLESCENTS WEIGHING AT LEAST 35 KG WHO ARE AT RISK FOR HIV-1 ACQUISITION |
| EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SUNLENCA | GILEAD SCIENCES INC | N215973 | Dec. 22, 2022 | RX | SOLUTION | SUBCUTANEOUS | 10654827 | Aug. 17, 2037 | IN COMBINATION WITH OTHER ANTIRETROVIRAL(S), FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY-TREATMENT EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION |
| EQ 300MG BASE | SUNLENCA | GILEAD SCIENCES INC | N215974 | Dec. 22, 2022 | RX | TABLET | ORAL | 10654827 | Aug. 17, 2037 | IN COMBINATION WITH OTHER ANTIRETROVIRAL(S), FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY-TREATMENT EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION |
| EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | YEZTUGO | GILEAD SCIENCES INC | N220018 | June 18, 2025 | RX | SOLUTION | SUBCUTANEOUS | 11807625 | Nov. 25, 2040 | FOR PRE-EXPOSURE PROPHYLAXIS TO REDUCE THE RISK OF SEXUALLY ACQUIRED HIV-1 IN ADULTS AND ADOLESCENTS WEIGHING AT LEAST 35 KG WHO ARE AT RISK FOR HIV-1 ACQUISITION |
| EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SUNLENCA | GILEAD SCIENCES INC | N215973 | Dec. 22, 2022 | RX | SOLUTION | SUBCUTANEOUS | 11944611 | Aug. 28, 2041 | IN COMBINATION WITH OTHER ANTIRETROVIRAL(S), FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY-TREATMENT EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION |
| EQ 300MG BASE | SUNLENCA | GILEAD SCIENCES INC | N215974 | Dec. 22, 2022 | RX | TABLET | ORAL | 11944611 | Aug. 28, 2041 | IN COMBINATION WITH OTHER ANTIRETROVIRAL(S), FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY-TREATMENT EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SUNLENCA | GILEAD SCIENCES INC | N215973 | Dec. 22, 2022 | RX | SOLUTION | SUBCUTANEOUS | Dec. 22, 2027 | NEW CHEMICAL ENTITY |
| EQ 300MG BASE | SUNLENCA | GILEAD SCIENCES INC | N215974 | Dec. 22, 2022 | RX | TABLET | ORAL | Dec. 22, 2027 | NEW CHEMICAL ENTITY |
| EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | YEZTUGO | GILEAD SCIENCES INC | N220018 | June 18, 2025 | RX | SOLUTION | SUBCUTANEOUS | Dec. 22, 2027 | NEW CHEMICAL ENTITY |
| EQ 300MG BASE | YEZTUGO | GILEAD SCIENCES INC | N220020 | June 18, 2025 | RX | TABLET | ORAL | Dec. 22, 2027 | NEW CHEMICAL ENTITY |
| EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | YEZTUGO | GILEAD SCIENCES INC | N220018 | June 18, 2025 | RX | SOLUTION | SUBCUTANEOUS | June 18, 2028 | NEW PRODUCT |
| EQ 300MG BASE | YEZTUGO | GILEAD SCIENCES INC | N220020 | June 18, 2025 | RX | TABLET | ORAL | June 18, 2028 | NEW PRODUCT |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Gag polyprotein | Polyprotein | INHIBITOR | Kd | 8.85 | DRUG LABEL | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| CHEBI:234519 | CHEBI |
| QNG | PDB_CHEM_ID |
| CHEMBL4594438 | ChEMBL_ID |
| C000730993 | MESH_SUPPLEMENTAL_RECORD_UI |
| 11446 | IUPHAR_LIGAND_ID |
| DB15673 | DRUGBANK_ID |
| 1351588006 | SNOMEDCT_US |
| 287801000202101 | SNOMEDCT_US |
| 4041942 | VANDF |
| C5244461 | UMLSCUI |
| CHEMBL4802249 | ChEMBL_ID |
| 11108 | INN_ID |
| 2283356-12-5 | SECONDARY_CAS_RN |
| D12161 | KEGG_DRUG |
| 133082658 | PUBCHEM_CID |
| 364535 | MMSL |
| 41171 | MMSL |
| d09962 | MMSL |
| 019243 | NDDF |
| 019244 | NDDF |
| A9A0O6FB4H | UNII |
| 2625651 | RXNORM |
| A9A0O6FB4H | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Sunlenca | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61958-3001 | TABLET, FILM COATED | 300 mg | ORAL | NDA | 33 sections |
| Sunlenca | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61958-3001 | TABLET, FILM COATED | 300 mg | ORAL | NDA | 33 sections |
| Yeztugo | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61958-3401 | TABLET, FILM COATED | 300 mg | ORAL | NDA | 31 sections |
| Yeztugo | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61958-3401 | TABLET, FILM COATED | 300 mg | ORAL | NDA | 31 sections |